Hua Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hua Liu has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Chun-Hui He
Guangzhou Women and Children’s Medical Center, Guangzhou, 510120 Guangdong, China
1 shared publication - Deyu Zhao
Department of Respiratory Medicine, Children’s Hospital of Nanjing Medical University, Nanjing, China
1 shared publication - Han Zhang
Department of Pediatric Respiratory Medicine, Shengjing Hospital of China Medical University, 36 Sanhao Street, Heping District, Shenyang, Liaoning 110004, China
1 shared publication - Hua Xu
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China
1 shared publication Jia-Cheng Xue
Department of Pediatrics, The First Clinical Medical College of Guangzhou University of Chinese Medicine
1 shared publication- Jian-Ping Liu
Centre for Evidence-based Chinese Medicine, Beijing University of Chinese Medicine, China
1 shared publication
Latest Publications
- Open Access
- 10 September 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1906125
Case Report: Clinical phenotypes and recombinant human growth hormone therapeutic exploration for a patient with Takenouchi-Kosaki syndrome harboring the CDC42 p.Arg68Gln variant
This study reports a pediatric patient harboring the heterozygous CDC42 variant (c. 203G > A, p. Arg68Gln), an ultra-rare variant with limited clinical and genetic data worldwide. She presented with typical Takenouchi-Kosaki syndrome (TKS) manifestations, including severe growth retardation, characteristic craniofacial dysmorphism, persistent macrothrombocytopenia and progressive sensorineural hearing loss. Additional evaluations identified leukopenia, hypogammaglobulinemia and a humoral immunodeficiency. Compound heterozygous GJB2 variants were detected but unlikely to dominate the patient's profound hearing loss. Off-label recombinant human growth hormone (rhGH) therapy was administered for her short stature. During six months of follow-up, favorable catch-up growth was achieved. Literature review was conducted to clarify features of this variant. This study supplements the clinical data of the CDC42 p. Arg68Gln variant, provides preliminary evidence for rhGH intervention, and offers reference information for the clinical management and genetic counseling of patients with TKS.
- 10 September 2026
- Published by Frontiers Media SA in Frontiers in Pediatrics
- Vol. 14, 1906125
Open AccessCase Report: Clinical phenotypes and recombinant human growth hormone therapeutic exploration for a patient with Takenouchi-Kosaki syndrome harboring the CDC42 p.Arg68Gln variant
This study reports a pediatric patient harboring the heterozygous CDC42 variant (c. 203G > A, p. Arg68Gln), an ultra-rare variant with limited clinical and genetic data worldwide. She presented with typical Takenouchi-Kosaki syndrome (TKS) manifestations, including severe growth retardation, characteristic craniofacial dysmorphism, persistent macrothrombocytopenia and progressive sensorineural hearing loss. Additional evaluations identified leukopenia, hypogammaglobulinemia and a humoral immunodeficiency. Compound heterozygous GJB2 variants were detected but unlikely to dominate the patient's profound hearing loss. Off-label recombinant human growth hormone (rhGH) therapy was administered for her short stature. During six months of follow-up, favorable catch-up growth was achieved. Literature review was conducted to clarify features of this variant. This study supplements the clinical data of the CDC42 p. Arg68Gln variant, provides preliminary evidence for rhGH intervention, and offers reference information for the clinical management and genetic counseling of patients with TKS.
- Open Access
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1811435
Research on the role of gut microbiota metabolites in autism by multi-omics and network pharmacology
Objective: The relationship and underlying mechanisms linking the gut microbiota, metabolites and autism spectrum disorder (ASD) have not been fully elucidated. Methods: In the present study, network pharmacology was combined with machine learning for a systematic investigation into the possible action mechanisms between metabolites derived from the gut microbiota and their targets in ASD. Subsequently, untargeted metabolomics analysis and 16S rRNA sequencing were utilized for investigating alterations in differential metabolites and the composition of principal gut microbiota between normal and BTBR mice. Results: The findings demonstrated that five characteristic targets: CXCR3, HCAR2, HTR1A, IL-6 and NFKB1 modulated by the gut microbiota and gut microbiota’s metabolites were significantly associated with ASD. The M-S-M-T network prioritized 21 candidate gut-microbiota-derived metabolites, including phenylacetic acid and coumarin. These candidates were generated from database-based target prediction and should be interpreted separately from the differential metabolites detected in fecal metabolomics. Metabolomic and 16S rRNA sequencing analyses revealed that BTBR mice displayed metabolic dysregulation and disrupted gut microbiota composition compared with normal ones. These findings suggest that phenylalanine metabolism and neuroactive ligand-receptor interaction may be associated with ASD-like behavioral phenotypes in BTBR mice and warrant further experimental validation. The gut microbiota-metabolite-behavior network analysis further uncovered significant associations among the behavioral characteristics of ASD, alterations in gut microbiota composition and markedly altered metabolite profiles. Conclusion: By integrating network pharmacology, transcriptomic re-analysis, fecal metabolomics and 16S rRNA sequencing, this study identifies candidate microbe-metabolite-target associations related to ASD-like phenotypes. These results provide testable hypotheses for future mechanistic studies of gut-brain communication in ASD.
- 4 August 2026
- Published by Frontiers Media SA in Frontiers in Microbiology
- Vol. 17, 1811435
Open AccessResearch on the role of gut microbiota metabolites in autism by multi-omics and network pharmacology
Objective: The relationship and underlying mechanisms linking the gut microbiota, metabolites and autism spectrum disorder (ASD) have not been fully elucidated. Methods: In the present study, network pharmacology was combined with machine learning for a systematic investigation into the possible action mechanisms between metabolites derived from the gut microbiota and their targets in ASD. Subsequently, untargeted metabolomics analysis and 16S rRNA sequencing were utilized for investigating alterations in differential metabolites and the composition of principal gut microbiota between normal and BTBR mice. Results: The findings demonstrated that five characteristic targets: CXCR3, HCAR2, HTR1A, IL-6 and NFKB1 modulated by the gut microbiota and gut microbiota’s metabolites were significantly associated with ASD. The M-S-M-T network prioritized 21 candidate gut-microbiota-derived metabolites, including phenylacetic acid and coumarin. These candidates were generated from database-based target prediction and should be interpreted separately from the differential metabolites detected in fecal metabolomics. Metabolomic and 16S rRNA sequencing analyses revealed that BTBR mice displayed metabolic dysregulation and disrupted gut microbiota composition compared with normal ones. These findings suggest that phenylalanine metabolism and neuroactive ligand-receptor interaction may be associated with ASD-like behavioral phenotypes in BTBR mice and warrant further experimental validation. The gut microbiota-metabolite-behavior network analysis further uncovered significant associations among the behavioral characteristics of ASD, alterations in gut microbiota composition and markedly altered metabolite profiles. Conclusion: By integrating network pharmacology, transcriptomic re-analysis, fecal metabolomics and 16S rRNA sequencing, this study identifies candidate microbe-metabolite-target associations related to ASD-like phenotypes. These results provide testable hypotheses for future mechanistic studies of gut-brain communication in ASD.
- Open Access
- 23 December 2013
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 13 (1) , 367
A cross-sectional study of the clinical characteristics of hospitalized children with community-acquired pneumonia in eight eastern cities in China
Community-acquired pneumonia in children is common in China. To understand current clinical characteristics and practice, we conducted a cross-sectional study to analyze quality of care on childhood pneumonia in eight eastern cities in China.
- 23 December 2013
- Published by Springer Nature in BMC Complementary and Alternative Medicine
- Vol. 13 (1) , 367
Open AccessA cross-sectional study of the clinical characteristics of hospitalized children with community-acquired pneumonia in eight eastern cities in China
Community-acquired pneumonia in children is common in China. To understand current clinical characteristics and practice, we conducted a cross-sectional study to analyze quality of care on childhood pneumonia in eight eastern cities in China.